1. Home
  2. PAXS vs IVA Comparison

PAXS vs IVA Comparison

Compare PAXS & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PAXS

PIMCO Access Income Fund of Beneficial Interest

N/A

Current Price

$13.26

Market Cap

664.0M

Sector

Finance

ML Signal

N/A

Logo Inventiva S.A. American Depository Shares

IVA

Inventiva S.A. American Depository Shares

N/A

Current Price

$3.48

Market Cap

796.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PAXS
IVA
Founded
N/A
2011
Country
United States
France
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
664.0M
796.1M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
PAXS
IVA
Price
$13.26
$3.48
Analyst Decision
Strong Buy
Analyst Count
0
13
Target Price
N/A
★ $15.55
AVG Volume (30 Days)
281.0K
★ 1.7M
Earning Date
01-01-0001
09-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,985.57
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.92
$3.11
52 Week High
$16.56
$7.98

Technical Indicators

Market Signals
Indicator
PAXS
IVA
Relative Strength Index (RSI) 37.63 38.22
Support Level $12.92 $3.23
Resistance Level $14.85 $4.80
Average True Range (ATR) 0.19 0.23
MACD 0.00 -0.01
Stochastic Oscillator 42.31 37.84

Price Performance

Historical Comparison
PAXS
IVA

About PAXS PIMCO Access Income Fund of Beneficial Interest

PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.

Share on Social Networks: